1. Intravitreal Dexamethasone Implant for Postoperative Macular Oedema Secondary to Vitrectomy for Epiretinal Membrane and Retinal Detachment: A Systematic Review and Meta-Analysis
- Author
-
Parisi, Guglielmo, Fallico, Matteo, Avitabile, Teresio, Longo, Antonio, Ortisi, Elina, Russo, Andrea, Petrillo, Francesco, Maugeri, Andrea, Barchitta, Martina, Bonfiglio, Vincenza, Furino, Claudio, Cennamo, Gilda, Caselgrandi, Paolo, Marolo, Paola, Ventre, Luca, and Reibaldi, Michele
- Subjects
genetic structures ,Article Subject - Abstract
Purpose. To evaluate the efficacy of intravitreal dexamethasone implant (DEX) for the treatment of macular oedema secondary to vitrectomy for epiretinal membrane (ERM) and retinal detachment (RD) by conducting a systematic review with meta-analysis of published studies. Methods. Studies reporting clinical outcomes of DEX use for the treatment of macular oedema secondary to ERM and RD vitrectomy were searched on PubMed and Embase databases. The primary outcome was best-corrected visual acuity (BCVA) change between baseline and post-DEX treatment, reported as mean difference (MD) with 95% confidence interval (CI). Mean central macular thickness (CMT) change was assessed as a secondary outcome. Postimplant adverse events, including intraocular pressure rise and cataract development, were reported as well. Results. Five uncontrolled studies, 1 nonrandomized controlled study, and 1 randomized controlled study were included, with a total of 5 cohorts and 3 cohorts in the ERM group and RD group, respectively. Considering the last available follow-up, a significant improvement in postimplant BCVA was found in the overall population, irrespective of the indication for vitrectomy (MD = −0.28, 95% CI = −0.37, −0.20; p
- Published
- 2021
- Full Text
- View/download PDF